What is the current valuation of the Hemophilia Gene Therapy Market?

The Hemophilia Gene Therapy Market was valued at 2.618 USD Billion in 2024. Read More

What is the projected market size for the Hemophilia Gene Therapy Market by 2035?

The market is projected to reach 15.22 USD Billion by 2035. Read More

What is the expected CAGR for the Hemophilia Gene Therapy Market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 17.35%. Read More

Which companies are considered key players in the Hemophilia Gene Therapy Market?

Key players include Spark Therapeutics, Bayer, Roche, BioMarin Pharmaceutical, Sangamo Therapeutics, uniQure, Pfizer, and Bristol-Myers Squibb. Read More

What are the main segments of the Hemophilia Gene Therapy Market?

The main segments include Gene Replacement Therapy, Gene Editing Therapy, and RNA Interference Therapy. Read More

How does the market segment for Hemophilia A compare to Hemophilia B?

In 2024, the market for Hemophilia A was valued at 1.309 USD Billion, while Hemophilia B was valued at 0.785 USD Billion. Read More

What administration methods are utilized in the Hemophilia Gene Therapy Market?

Administration methods include Intravenous, Subcutaneous, and Intradermal, with respective valuations of 0.9, 0.8, and 0.918 USD Billion in 2024. Read More

What are the end-user segments in the Hemophilia Gene Therapy Market?

End-user segments include Hospitals, Specialized Clinics, and Home Care Settings, with Home Care Settings valued at 1.048 USD Billion in 2024. Read More

What is the market valuation for Gene Replacement Therapy in 2024?

Gene Replacement Therapy was valued at 1.309 USD Billion in 2024. Read More

How does the market for RNA Interference Therapy compare to other therapies?

In 2024, RNA Interference Therapy was valued at 0.524 USD Billion, indicating a smaller market share compared to Gene Replacement and Gene Editing Therapies. Read More

Hemophilia Gene Therapy Market

ID: MRFR/HC/35092-HCR

128 Pages

Satyendra Maurya

Last Updated: April 24, 2026

Hemophilia Gene Therapy Market Research Report: Size, Share, Trend Analysis By Therapy Type (Gene Replacement Therapy, Gene Editing Therapy, RNA Interference Therapy), By Hemophilia Type (Hemophilia A, Hemophilia B, Acquired Hemophilia), By Administration Method (Intravenous, Subcutaneous, Intradermal), By End Users (Hospitals, Specialized Clinics, Home Care Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Gene Replacement Therapy
  2. 4.1.2 Gene Editing Therapy
  3. 4.1.3 RNA Interference Therapy
2. 4.2 Healthcare, BY Hemophilia Type (USD Billion)
  1. 4.2.1 Hemophilia A
  2. 4.2.2 Hemophilia B
  3. 4.2.3 Acquired Hemophilia
3. 4.3 Healthcare, BY Administration Method (USD Billion)
  1. 4.3.1 Intravenous
  2. 4.3.2 Subcutaneous
  3. 4.3.3 Intradermal
4. 4.4 Healthcare, BY End User (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Specialized Clinics
  3. 4.4.3 Home Care Settings
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Spark Therapeutics (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 BioMarin Pharmaceutical (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sangamo Therapeutics (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 uniQure (NL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bristol-Myers Squibb (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY HEMOPHILIA TYPE
5. 6.5 US MARKET ANALYSIS BY ADMINISTRATION METHOD
6. 6.6 US MARKET ANALYSIS BY END USER
7. 6.7 CANADA MARKET ANALYSIS BY TYPE
8. 6.8 CANADA MARKET ANALYSIS BY HEMOPHILIA TYPE
9. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION METHOD
10. 6.10 CANADA MARKET ANALYSIS BY END USER
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY HEMOPHILIA TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION METHOD
15. 6.15 GERMANY MARKET ANALYSIS BY END USER
16. 6.16 UK MARKET ANALYSIS BY TYPE
17. 6.17 UK MARKET ANALYSIS BY HEMOPHILIA TYPE
18. 6.18 UK MARKET ANALYSIS BY ADMINISTRATION METHOD
19. 6.19 UK MARKET ANALYSIS BY END USER
20. 6.20 FRANCE MARKET ANALYSIS BY TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY HEMOPHILIA TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION METHOD
23. 6.23 FRANCE MARKET ANALYSIS BY END USER
24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY HEMOPHILIA TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION METHOD
27. 6.27 RUSSIA MARKET ANALYSIS BY END USER
28. 6.28 ITALY MARKET ANALYSIS BY TYPE
29. 6.29 ITALY MARKET ANALYSIS BY HEMOPHILIA TYPE
30. 6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION METHOD
31. 6.31 ITALY MARKET ANALYSIS BY END USER
32. 6.32 SPAIN MARKET ANALYSIS BY TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY HEMOPHILIA TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION METHOD
35. 6.35 SPAIN MARKET ANALYSIS BY END USER
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY HEMOPHILIA TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION METHOD
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TYPE
42. 6.42 CHINA MARKET ANALYSIS BY HEMOPHILIA TYPE
43. 6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION METHOD
44. 6.44 CHINA MARKET ANALYSIS BY END USER
45. 6.45 INDIA MARKET ANALYSIS BY TYPE
46. 6.46 INDIA MARKET ANALYSIS BY HEMOPHILIA TYPE
47. 6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION METHOD
48. 6.48 INDIA MARKET ANALYSIS BY END USER
49. 6.49 JAPAN MARKET ANALYSIS BY TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY HEMOPHILIA TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION METHOD
52. 6.52 JAPAN MARKET ANALYSIS BY END USER
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY HEMOPHILIA TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION METHOD
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY HEMOPHILIA TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION METHOD
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USER
61. 6.61 THAILAND MARKET ANALYSIS BY TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY HEMOPHILIA TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION METHOD
64. 6.64 THAILAND MARKET ANALYSIS BY END USER
65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY HEMOPHILIA TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION METHOD
68. 6.68 INDONESIA MARKET ANALYSIS BY END USER
69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY HEMOPHILIA TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION METHOD
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USER
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY HEMOPHILIA TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION METHOD
77. 6.77 BRAZIL MARKET ANALYSIS BY END USER
78. 6.78 MEXICO MARKET ANALYSIS BY TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY HEMOPHILIA TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION METHOD
81. 6.81 MEXICO MARKET ANALYSIS BY END USER
82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY HEMOPHILIA TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION METHOD
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USER
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY HEMOPHILIA TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION METHOD
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY HEMOPHILIA TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION METHOD
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY HEMOPHILIA TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION METHOD
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY HEMOPHILIA TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION METHOD
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USER
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY HEMOPHILIA TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY HEMOPHILIA TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY ADMINISTRATION METHOD, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY ADMINISTRATION METHOD, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY HEMOPHILIA TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY ADMINISTRATION METHOD, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Hemophilia Gene Therapy Market Segmentation

Hemophilia Gene Therapy Market By Type (USD Billion, 2025-2035)

Gene Replacement Therapy
Gene Editing Therapy
RNA Interference Therapy

Hemophilia Gene Therapy Market By Hemophilia Type (USD Billion, 2025-2035)

Hemophilia A
Hemophilia B
Acquired Hemophilia

Hemophilia Gene Therapy Market By Administration Method (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Intradermal

Hemophilia Gene Therapy Market By End User (USD Billion, 2025-2035)

Hospitals
Specialized Clinics
Home Care Settings

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”